-
公开(公告)号：US20230251247A1
公开(公告)日：2023-08-10
申请号：US18104578
申请日：2023-02-01
CPC分类号： G01N33/5308 , G01N33/6893 , A61K47/60 , A61P19/02 , A61K9/0019 , A61K38/44 , C12Y107/03003 , G01N2800/107 , G01N2800/52 , G01N2800/56 , G01N2333/90694
摘要： Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
-
公开(公告)号：US20230173035A1
公开(公告)日：2023-06-08
申请号：US17955437
申请日：2022-09-28
发明人： Jeffrey D. KENT , Brian LAMOREAUX , John BOTSON , Jeff PETERSON
IPC分类号： A61K38/44 , A61K47/34 , A61P19/06 , A61K31/519
CPC分类号： A61K38/44 , A61K47/34 , A61P19/06 , A61K31/519
摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
-
公开(公告)号：US11598767B2
公开(公告)日：2023-03-07
申请号：US17934119
申请日：2022-09-21
摘要： Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
-
公开(公告)号：US20230028134A1
公开(公告)日：2023-01-26
申请号：US17934119
申请日：2022-09-21
摘要： Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
-
公开(公告)号：US20240026312A1
公开(公告)日：2024-01-25
申请号：US18376684
申请日：2023-10-04
发明人： Meir FISCHER , Eliyahu HAROSH
CPC分类号： C12N9/0048 , C07K1/30 , C07K14/565 , C07K16/00 , C07K16/36 , C12P21/02 , C12Y107/03003 , C07K2317/622 , C07K2317/76
摘要： The subject invention provides a method for purifying a target protein from a mixture comprising the target protein and contaminating protein, comprising the steps of exposing the mixture to an effective amount of a cationic surfactant such that the contaminating protein is preferentially precipitated and recovering the target protein. Proteins purified according to the method of the invention are also provided.
-
公开(公告)号：US11781119B2
公开(公告)日：2023-10-10
申请号：US17724091
申请日：2022-04-19
发明人： Jacob Hartman , Simona Mendelovitz
CPC分类号： C12N9/0048 , A61K38/44 , A61K47/60 , C12N9/0046 , C12Y107/03003
摘要： Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
-
公开(公告)号：US20230085022A1
公开(公告)日：2023-03-16
申请号：US16347900
申请日：2017-11-10
发明人： Jeffrey D. KENT , Brian LAMOREAUX
IPC分类号： A61K38/44 , A61K9/00 , A61K31/573 , A61K31/519 , A61K31/381 , A61P37/00
摘要： Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and/or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.
-
公开(公告)号：US12121566B2
公开(公告)日：2024-10-22
申请号：US16777625
申请日：2020-01-30
发明人： Jeffrey D. Kent , Brian Lamoreaux
CPC分类号： A61K38/44 , A61K9/0053 , A61K31/52 , A61P19/06
摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
-
公开(公告)号：US20240255496A1
公开(公告)日：2024-08-01
申请号：US18630584
申请日：2024-04-09
CPC分类号： G01N33/5308 , A61K9/0019 , A61K38/44 , A61K47/60 , A61P19/02 , C12Y107/03003 , G01N33/6893 , G01N2333/90694 , G01N2800/107 , G01N2800/52 , G01N2800/56
摘要： Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
-
公开(公告)号：US20230034252A1
公开(公告)日：2023-02-02
申请号：US17724091
申请日：2022-04-19
发明人： Jacob HARTMAN , Simona MENDELOVITZ
摘要： Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.022 秒)
